BCL2 and neoplasm: utilized the co-delivery of Bcl-2-specific siRNA and paclitaxel through a liposomal nanoformulation with the aim of silencing Bcl-2-mediated signaling pathways and suppression of tumor growth in human breast cancer MDA-MB-231 cells and in a 4T1 mouse model to facilitate the reversal of drug resistance [202].